Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation.

摘要: A 44-year-old woman underwent left single-lung transplantation for end-stage emphysema due to α1-antitrypsin deficiency in January 2010. Cyclosporine, azathioprine, and prednisolone were administered immunosuppression antithymocyte globulin induction therapy at the time of transplantation. Routine examination a lung biopsy, 4 months after transplantation, showed nonspecific, diffuse interstitial inflammation with alveolar septal fibrosis. The patient's clinical status imaging studies, consistent nonspecific pneumonitis, which was considered as signs acute rejection, worsened within 2 weeks, despite high-dose steroids, change calcineurin inhibitor, plasmapheresis. Within few days single, 10-mg, intravenous dose alemtuzumab, health improved markedly. She has remained stable on standard, ambulatory, posttransplant antirejection drug regimen. We have since successfully treated alemtuzumab three additional patients who developed injury are also summarized this report.